Ceftazidime

Kathryn Dzintars, Pharm.D., BCPS, Paul A. Pham, Pharm.D.
Pediatric Dosing Author: Alice Jenh Hsu, PharmD, BCPS, AQ-ID

Ceftazidime is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please sign in or purchase a subscription.

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

Lower respiratory tract infections including pneumonia caused by P. aeruginosa and other Pseudomonas spp., H. influenzae, Klebsiella spp., Enterobacter spp., P. mirabilis, E. coli, Serratia spp., and Citrobacter spp.
- Note: cefotaxime or ceftriaxone preferred for S. pneumoniae.
Skin and skin-structure infections caused by P. aeruginosa, Klebsiella spp., E. coli,Proteus spp. including P. mirabilisand indole-positive Proteus, Enterobacter spp., and Serratia spp.
Complicated and uncomplicated urinary tract infections caused by P. aeruginosa,Enterobacter spp., Proteus spp., including P. mirabilis and indole-positive Proteus, Klebsiella spp. and E. coli
Septicemia caused by P. aeruginosa, Klebsiella spp., H. influenzae, E. coli, and Serratia spp.
- Note: cefotaxime or ceftriaxone preferred for S. pneumoniae.
Bone and joint infections caused by P. aeruginosa, Klebsiella spp., and Enterobacter spp.
Gynecologic infections (endometritis, pelvic cellulitis, and other GYN infections) caused by E. coli
Intra-abdominal Infections, including peritonitis caused by E. coli, Klebsiella spp., and polymicrobial infections caused by aerobic and anaerobic organisms (in combination with metronidazole)
Central nervous system infections including meningitis, caused by H. influenzae , N. meningitidis, and P. aeruginosa
- Note: cefotaxime or ceftriaxone preferred for S. pneumoniae

NON-FDA APPROVED USES

Shunt infections
Diabetic foot infection (in combination with clindamycin)

-- To view the remaining sections of this topic, please sign in or purchase a subscription --

Last updated: December 6, 2017

Citation

Dzintars, Kathryn, and Paul A Pham. "Ceftazidime." Johns Hopkins ABX Guide, The Johns Hopkins University, 2017. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540101/all/Ceftazidime.

Dzintars K, Pham PA. Ceftazidime. Johns Hopkins ABX Guide. The Johns Hopkins University; 2017. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540101/all/Ceftazidime. Accessed January 23, 2019.

Dzintars, K., & Pham, P. A. (2017). Ceftazidime. In Johns Hopkins ABX Guide. Available from https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540101/all/Ceftazidime

Dzintars K, Pham PA. Ceftazidime [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2017. [cited 2019 January 23]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540101/all/Ceftazidime

* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case

TY - ELEC T1 - Ceftazidime ID - 540101 A1 - Dzintars,Kathryn,Pharm.D., BCPS AU - Pham,Paul,Pharm.D. Y1 - 2017/12/06/ BT - Johns Hopkins ABX Guide UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540101/all/Ceftazidime PB - The Johns Hopkins University DB - Pediatrics Central DP - Unbound Medicine ER -